BACKGROUND: Type G immunoglobulins against ADAMTS13 are the primary cause of acquired (idiopathic) thrombotic thrombocytopenic purpura. However, the domains of ADAMTS13 which the type G anti-ADAMT13 immunoglobulins target have not been investigated in a large cohort of patients with thrombotic thrombocytopenic purpura. DESIGN AND METHODS: Sixty-seven patients with acquired idiopathic thrombotic thrombocytopenic purpura were prospectively collected from three major U.S. centers. An enzyme-linked immunosorbent assay determined plasma concentrations of anti-ADAMTS13 type G immunoglobulins, whereas immunoprecipitation plus western blotting determined the binding domains of these type G immunoglobulins. RESULTS: Plasma anti-ADAMTS13 type G immunoglobulins from 67 patients all bound full-length ADAMTS13 and a variant truncated after the eighth TSP1 repeat (delCUB). Approximately 97% (65/67) of patients harbored type G immunoglobulins targeted against a variant truncated after the spacer domain (MDTCS). However, only 12% of patients' samples reacted with a variant lacking the Cys-rich and spacer domains (MDT). In addition, approximately 37%, 31%, and 46% of patients' type G immunoglobulins interacted with the ADAMTS13 fragment containing TSP1 2-8 repeats (T2-8), CUB domains, and TSP1 5-8 repeats plus CUB domains (T5-8CUB), respectively. The presence of type G immunoglobulins targeted against the T2-8 and/or CUB domains was inversely correlated with the patients' platelet counts on admission. CONCLUSIONS: This multicenter study further demonstrated that the multiple domains of ADAMTS13, particularly the Cys-rich and spacer domains, are frequently targeted by anti-ADAMTS13 type G immunoglobulins in patients with acquired (idiopathic) thrombotic thrombocytopenic purpura. Our data shed more light on the pathogenesis of acquired thrombotic thrombocytopenic purpura and provide further rationales for adjunctive immunotherapy.
BACKGROUND: Type G immunoglobulins against ADAMTS13 are the primary cause of acquired (idiopathic) thrombotic thrombocytopenic purpura. However, the domains of ADAMTS13 which the type G anti-ADAMT13 immunoglobulins target have not been investigated in a large cohort of patients with thrombotic thrombocytopenic purpura. DESIGN AND METHODS: Sixty-seven patients with acquired idiopathic thrombotic thrombocytopenic purpura were prospectively collected from three major U.S. centers. An enzyme-linked immunosorbent assay determined plasma concentrations of anti-ADAMTS13 type G immunoglobulins, whereas immunoprecipitation plus western blotting determined the binding domains of these type G immunoglobulins. RESULTS: Plasma anti-ADAMTS13 type G immunoglobulins from 67 patients all bound full-length ADAMTS13 and a variant truncated after the eighth TSP1 repeat (delCUB). Approximately 97% (65/67) of patients harbored type G immunoglobulins targeted against a variant truncated after the spacer domain (MDTCS). However, only 12% of patients' samples reacted with a variant lacking the Cys-rich and spacer domains (MDT). In addition, approximately 37%, 31%, and 46% of patients' type G immunoglobulins interacted with the ADAMTS13 fragment containing TSP1 2-8 repeats (T2-8), CUB domains, and TSP1 5-8 repeats plus CUB domains (T5-8CUB), respectively. The presence of type G immunoglobulins targeted against the T2-8 and/or CUB domains was inversely correlated with the patients' platelet counts on admission. CONCLUSIONS: This multicenter study further demonstrated that the multiple domains of ADAMTS13, particularly the Cys-rich and spacer domains, are frequently targeted by anti-ADAMTS13 type G immunoglobulins in patients with acquired (idiopathic) thrombotic thrombocytopenic purpura. Our data shed more light on the pathogenesis of acquired thrombotic thrombocytopenic purpura and provide further rationales for adjunctive immunotherapy.
Authors: G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai Journal: Nature Date: 2001-10-04 Impact factor: 49.962
Authors: Christoph Klaus; Barbara Plaimauer; Jan-Dirk Studt; Friedrich Dorner; Bernhard Lämmle; Pier Mannuccio Mannucci; Friedrich Scheiflinger Journal: Blood Date: 2004-02-19 Impact factor: 22.113
Authors: Friedrich Scheiflinger; Paul Knöbl; Bettina Trattner; Barbara Plaimauer; Gabriele Mohr; Michael Dockal; Friedrich Dorner; Manfred Rieger Journal: Blood Date: 2003-07-10 Impact factor: 22.113
Authors: Sara K Vesely; James N George; Bernhard Lämmle; Jan-Dirk Studt; Lorenzo Alberio; Mayez A El-Harake; Gary E Raskob Journal: Blood Date: 2003-03-13 Impact factor: 22.113
Authors: Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng Journal: Blood Date: 2012-01-30 Impact factor: 22.113
Authors: Silvia Ferrari; Kristina Palavra; Bernadette Gruber; Johanna A Kremer Hovinga; Paul Knöbl; Claudine Caron; Caroline Cromwell; Louis Aledort; Barbara Plaimauer; Peter L Turecek; Hanspeter Rottensteiner; Friedrich Scheiflinger Journal: Haematologica Date: 2013-11-15 Impact factor: 9.941
Authors: Simon J Foulcer; Courtney M Nelson; Maritza V Quintero; Balagurunathan Kuberan; Jonathan Larkin; Maria T Dours-Zimmermann; Dieter R Zimmermann; Suneel S Apte Journal: J Biol Chem Date: 2014-08-13 Impact factor: 5.157
Authors: Rana Grillberger; Veronica C Casina; Peter L Turecek; X Long Zheng; Hanspeter Rottensteiner; Friedrich Scheiflinger Journal: Haematologica Date: 2014-02-14 Impact factor: 9.941
Authors: Eric M Ostertag; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; X Long Zheng; Douglas B Cines; Don L Siegel Journal: Transfusion Date: 2016-04-04 Impact factor: 3.157
Authors: Mohammad S Abdelgawwad; Wenjing Cao; Liang Zheng; Nicole K Kocher; Lance A Williams; X Long Zheng Journal: Arterioscler Thromb Vasc Biol Date: 2018-11 Impact factor: 8.311
Authors: Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel Journal: Blood Date: 2012-09-10 Impact factor: 22.113